Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

J Neuroinflammation. 2014 Feb 27:11:37. doi: 10.1186/1742-2094-11-37.


Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury.

Findings: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes.

Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged, 80 and over
  • Animals
  • Brain Injuries / cerebrospinal fluid
  • Brain Injuries / drug therapy*
  • Brain Injuries / immunology*
  • Cytokines / metabolism
  • Disease Models, Animal
  • Female
  • Glasgow Coma Scale
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunologic Factors / therapeutic use*
  • Lysophospholipids / cerebrospinal fluid
  • Lysophospholipids / immunology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Single-Blind Method
  • Young Adult


  • Cytokines
  • Immunoglobulin G
  • Immunologic Factors
  • Lysophospholipids
  • lysophosphatidic acid